Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded in3 project) is driven
Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market. The funding comes from
The retina is the means through which most people primarily perceive the world and for children particularly, visual defects can affect educational, social and emotional development.1 The importance of retinal disease, in
Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin, pre-mRNA processing factors and usherin. The genes
Dr Colin Brown will be presenting two posters at 22nd North American Meeting of the International Society for the Study of Xenobiotics.
Newcells Biotech has secured a £2 million investment from NVM Private Equity and Northstar Ventures to support its ambitious growth plans.
Age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. This review article by Dr Valeria Chichagova and Dr Dean Hallam provides an overview of progress made, ongoing studies and challenges ahead.
If you are attending the World Preclinical Congress and would like to arrange a meeting with Dr Colin Brown, then please let us know.
Dr Valeria Chichagova will be presenting at the inaugural Faculty of Medical Science (FMS) Post-Doc Symposium on Friday 15th June 2018.